Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immune Impact of Plerixafor in Advanced Pancreatic, Ovarian, and Colorectal Cancer
NCT02179970Phase 1Completed
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Jun 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in pancreatic adenocarcinoma (PDAC), ovarian serous adenocarcinoma and colorectal adenocarcinoma, sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Safety of Investigational Medicinal Product (IMP) at 24 months. Started Jun 2015; status: completed.
02
Drugs
plerixafor
03
Conditions
pancreatic adenocarcinoma (PDAC)ovarian serous adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on NCT02179970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179970.